Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.35 |
| ▸ | CTSD | P07339 | 4/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17326070 | 1.00 | BACE1 (0.35) | BACE1CTSDBACE2 | |
| SCHEMBL17326055 | 0.87 | BACE1 (0.46) | BACE1CTSDBACE2 | |
| SCHEMBL13467261 | 0.84 | BACE1 (0.39) | BACE1CTSDBACE2 | |
| SCHEMBL13466086 | 0.84 | BACE1 (0.39) | BACE1CTSDBACE2 | |
| SCHEMBL23333905 | 0.82 | BACE1 (0.30) | BACE1 | |
| SCHEMBL18791552 | 0.78 | — | — | |
| SCHEMBL17326057 | 0.77 | BACE1 (0.58) | BACE1CTSDBACE2 | |
| SCHEMBL17326052 | 0.76 | BACE1 (0.46) | BACE1CTSDBACE2 | |
| SCHEMBL17326031 | 0.74 | BACE1 (0.35) | BACE1CTSDBACE2 | |
| SCHEMBL17326049 | 0.74 | BACE1 (0.42) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732088-B2 | C2-carbocyclic iminothiazine dioxides as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732088-B2 | C2-carbocyclic iminothiazine dioxides as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170114065-A1 | C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114065-A1 | C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| WO-2015187437-A1 | C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114065-A1 | C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE2, BACE1, APP | BACE1 2/4885CTSD 534/4885BACE2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.